- If you have any queries please email firstname.lastname@example.org
|31 July 2023
|Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
|10 August 2018
|The National Institute for Health and Care Excellence (NICE) has been asked to consider an evaluation of VTS-270 for treating Niemann-Pick type C1 ID1267. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this proposed evaluation. On receiving updated regulatory timing information from the company that will market the technology, NICE has agreed that holding a scoping workshop at this time would not be appropriate. Consequently the scoping workshop arranged for the 14 September 2018 will be cancelled and the consultation on the draft scope will not continue. The workshop and consultation will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause. If you have any comments or concerns please contact the project manager for this proposed appraisal Michelle Adhemar on 44 (0)20 7045 2239 or via email on email@example.com
For further information on our processes and methods, please see our CHTE processes and methods manual